Table 3.

Cumulative incidence of 12-month NRM for key subsets using the threshold corresponding to the concordance probability

Subset	AUC	ST2+REG3α			AUC	AREG
		CI 12 mo NRM	P value	Correctly classified		CI 12 mo NRM	P value	Correctly classified
Validation cohort (n = 374)
Minnesota high risk (n = 53)	0.689	24% vs 48%	.083	29 (55%)	0.780	8% vs 53%	.013	33 (62%)
Minnesota standard risk (n = 321)	0.720	9% vs 34%	<.001	250 (79%)	0.636	11% vs 21%	.003	200 (62%)
LGI involvement (n = 109)	0.790	12% vs 48%	<.001	73 (67%)	0.773	8% vs 45%	<.001	66 (61%)
Skin only involvement (n = 199)	0.629	8% vs 22%	<.001	155 (79%)	0.563	10% vs 13%	.218	129 (65%)
PT-CY prophylaxis (n = 133)	0.717	12% vs 35%	<.001	100 (75%)	0.595	14% vs 21%	.22	83 (62%)
Systemically treated (n = 321)	0.739	12% vs 39%	<.001	231 (72%)	0.693	12% vs 30%	<.001	195 (61%)
Systemically treated subset (n = 321)
Minnesota high risk (n = 52)	0.679	26% vs 48%	.116	28 (54%)	0.780	8% vs 54%	.011	33 (63%)
Minnesota standard risk (n = 269)	0.700	12% vs 35%	<.001	203 (75%)	0.617	13% vs 23%	.022	162 (60%)
LGI involvement (n = 104)	0.777	14% vs 49%	<.001	68 (65%)	0.768	9% vs 46%	<.001	63 (61%)
Skin only involvement (n = 158)	0.610	11% vs 24%	.034	116 (73%)	0.555	13% vs 16%	.489	99 (63%)
PT-CY prophylaxis (n = 125)	0.711	13% vs 35%	.005	94 (75%)	0.592	16% vs 23%	.233	72 (58%)

LGI, lower gastrointestinal tract.